Brief: Hybrigenics Continues To Develop Treatment Of Diseases Through Use Of Adipose Tissue Cell Derivatives
04/05/2020 17:30
May 4 (Reuters) - Hybrigenics SA ALHYG.PA :
* HYBRIGENICS AND ITS SUBSIDIARIES CONTINUE TO WORK ON
PRECLINICAL
AND CLINICAL DEVELOPMENTS FOR TREATMENT OF DISEASES USING FAT
CELL DERIVATIVES
* DMS BIOTECH CONTINUES WORK ON DESIGN AND DEVELOPMENT OF
INNOVATIVE TECHNICAL SOLUTIONS
Source text for Eikon: ID:nNDL1JYxbW
Further company coverage: ALHYG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Aton SA
See all newsBrief: Hybrigenics SA Says Hybrigenics Re-Brands To 'Aton', Commits EUR 15Million To Support Its New Growth And Development Strategy Over Next Three Years
Brief: Hybrigenics 2022 Net Loss EUR 0.5 Million
Brief: Hybrigenics Presents Progress Of B Cell Design Subsidiary
Brief: Hybrigenics Targets EUR 60 Mln Of Turnover By 2025
Brief: Hybrigenics H1 Operating Loss Widens To EUR 0.2 Million